How physical AI is rewiring pharma manufacturing

At first glance, the production floor appears almost empty. Behind thick glass isolators, robotic arms glide silently through sterile enclosures, transferring vials with mechanical precision. Cameras inspect each movement, while sensor networks track microscopic variations in temperature, airflow and particle counts. The environment is controlled, quiet and nearly autonomous. A decade ago, such precision would have seemed experimental, but today it marks the frontier of pharmaceutical production: physical artificial intelligence (AI). 

Several structural forces are accelerating interest in physical AI across life sciences manufacturing. Chief among them is the rapid expansion of biologics, with pipelines now dominated by therapies such as monoclonal antibodies and cell and gene therapies. Unlike small molecules, these drugs require complex sterile settings, flexible production infrastructure and smaller batch sizes. The sustained growth in injectable biologics is reflected in the global aseptic fill-finish market, which was valued at $6.48 billion in 2025 and is projected to reach $8.1 billion by 2030 (CAGR of 7%). These shifts are pushing manufacturers towards more adaptive infrastructure. 

Workforce constraints add another layer of pressure. While operating aseptic environments demands highly specialist skills, there remains a shortage of trained operators, since training cycles often span several years.  

The World Economic Forum has identified physical AI as a potential response to labour shortages, rising costs and supply chain fragility. “We are moving from the experimentation and hype stage to the ‘How am I using it to improve my business?’ stage,” observes Pete Lyons, a vice chair at Deloitte and the company’s US Life Sciences Sector Leader in 2025.  

His point captures a broader transition: AI and automation are evolving from pilot projects into core operational capabilities. Meanwhile, tightening regulatory expectations around contamination control, data integrity and traceability make reduced human intervention not only a productivity goal but a quality imperative.

Physical AI rests on three interconnected technology domains. Advanced robotics form the physical backbone, enabling automated handling of vials, syringes and singleuse components under strict aseptic conditions.

Computer vision serves as the sensory layer, detecting anomalies, verifying product quality and guiding robotic precision. Sensor networks and realtime data platforms deliver continuous feedback on temperature, pressure, particle counts and flow rates. And finally, AI orchestration layers analyse these data streams and coordinate machine actions across production lines, creating closedloop systems capable of responding dynamically to process variations. In aseptic operations, this approach markedly reduces reliance on manual intervention – long recognised as a prime contamination risk.

Emerging use cases illustrate this potential. At INTERPHEX 2026, Angelo Stracquatanio, CEO of Apprentice.io, based in Jersey City, New Jersey, will highlight implementations ranging from aseptic fillfinish to cell therapy. In fillfinish lines, robotic systems already perform vial filling, stoppering and inspection, and physical AI could extend these capabilities towards autonomous optimisation and realtime contamination monitoring.

For cell and gene therapies – an area still dependent on manual precision – automation can replicate human dexterity while elevating operators into supervisory roles. “Automation and robotics are increasingly being introduced to reduce human intervention and improve reproducibility,” notes Firouz Asgarzadeh, president of OSD Pharmaceutical Solutions, based in Irvine, California.

“Softwaredefined production lines could enable rapid product changeovers while maintaining GMP compliance,” added Troy Ostreng, senior product manager at Colder Products Company, based in St. Paul, Minnesota.

Physical AI is also recasting pharmaceutical manufacturing at the geopolitical level, since its potential advantages – continuous operations, higher quality control and improved safety – make it strategically valuable. Autonomous systems can enable roundtheclock production without major facility expansion. Machine vision solutions detect defects earlier than manual inspection and reduced human presence limits exposure to hazardous materials. 

These capabilities intersect with broader shifts in global chains. The COVID19 pandemic exposed structural vulnerabilities, prompting governments to prioritise domestic manufacturing capacity for critical medicines.

In the US, recent policy measures have accelerated plant approvals and incentivised onshoring of advanced manufacturing. Parallel initiatives have been launched in Europe, while Asian hubs – including China, Singapore and South Korea – continue to expand investment in digital biomanufacturing. In this new landscape, highly automated facilities are strategic assets. Nations that deploy autonomous bioproduction systems will gain a competitive edge in complex biologics while sustaining rigorous quality standards. Physical AI is thus emerging not only as a technological milestone but also as a lever of industrial sovereignty.

Pharmaceutical leaders such as Novartis, Pfizer and Roche have committed substantial investment to digital transformation under the Pharma 4.0 initiative. Novartis has allocated $80 million to advanced automation at its Schweizerhalle site – focused on siRNA manufacturing – and $26 million to sterile processing upgrades in Stein, Switzerland. These projects exemplify how major players are laying the foundations for the deployment of physical AI at scale, using networked production systems to achieve tangible operational gains. 

This transformation is global, with Asian manufacturers also integrating AI into core operations. At the Shanghai-based company Henlius Biotech, an executivelevel AI function drives machinelearning, automation and analytics integration across R&D and manufacturing, demonstrating how AI now underpins industrial strategy. 

Meanwhile, the traditional lines between robotics providers, software developers and engineering integrators are blurring. Through crossindustry collaboration, unified production platforms are emerging in a model that approaches the pharmaceutical factory as a ‘softwaredefined system’. This enables production capacity, product configurations and facility layout to be dynamically orchestrated through digital control layers, enabling levels of flexibility well beyond conventional manufacturing.

The shift towards autonomous pharmaceutical manufacturing depends as much on regulatory evolution as on technology itself. Good manufacturing practice (GMP) frameworks remain foundational but require reinterpretation to accommodate systems that make autonomous process adjustments. Such cases raise critical questions of accountability: if an algorithm modifies a process parameter, who bears responsibility? Regulators also need to determine how algorithmic behaviour can be validated, audited and monitored over time. Defining acceptable thresholds of human supervision is becoming a central challenge.

Industry bodies are beginning to engage with these issues. They include the International Society for Pharmaceutical Engineering (ISPE), which is developing guidance on AIenabled systems through its good, automated manufacturing practice (GAMP) framework. Taylor Chartier, cochair of the ISPE GAMP AI working group, underscores the need for robust governance to uphold patient safety, product quality, and data integrity – the three pillars of GMP. The forthcoming guidance adopts a riskbased, lifecycle approach intended to provide a shared reference for both regulators and manufacturers. Such frameworks are likely to prove decisive in shaping how quickly physical AI gains traction across global biomanufacturing networks.

The vision of fully autonomous pharmaceutical production – sometimes called ‘lightsout manufacturing’ – is moving steadily closer. Physical AI is accelerating that trajectory, allowing robotic systems to execute core operations while AI platforms continuously optimise in real time. Human roles are shifting, rather than disappearing: operators focus on oversight, validation and compliance, reflecting a deeper model of human–machine collaboration. 

While major challenges remain – chief among them system integration, regulatory acceptance and capital intensity – the direction of travel is unmistakable. The question is no longer whether physical AI will redefine pharmaceutical manufacturing, but how quickly companies and regulators can adapt to a fundamentally new industrial model.